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Infection by many viruses begins with fusion of viral and cellular lipid membranes, followed by
entry of viral contents into the target cell and ultimately, after many biochemical steps, integration
of viral DNA into that of the host cell. The early steps of membrane fusion and viral capsid entry are
mediated by adsorption to the cell surface, and receptor and coreceptor binding. HIV-1 specifically
targets CD4+ helper T-cells of the human immune system and binds to the receptor CD4 and
coreceptor CCR5 before fusion is initiated. Previous experiments have been performed using a cell
line (293-Affinofile) in which the expression of CD4 and CCR5 concentration were independently
controlled. After exposure to HIV-1 of various strains, the resulting infectivity was measured through
the fraction of infected cells. To design and evaluate the effectiveness of drug therapies that target
the inhibition of the entry processes, an accurate functional relationship between the CD4/CCR5
concentrations and infectivity is desired in order to more quantitatively analyze experimental data.
We propose three kinetic models describing the possible mechanistic processes involved in HIV entry
and fit their predictions to infectivity measurements, contrasting and comparing different outcomes.
Our approach allows interpretation of the clustering of infectivity of different strains of HIV-1 in
the space of mechanistic kinetic parameters. Our model fitting also allows inference of nontrivial
stoichiometries of receptor and coreceptor binding and provides a framework through which to
quantitatively investigate the effectiveness of fusion inhibitors and neutralizing antibodies.
I. INTRODUCTION
Despite their great adaptability and capacity to survive
in many different environments, viruses are not equipped
with the necessary biochemical materials, structures, or
metabolic resources to self replicate [1–8]. In order for a
virus strain to survive, it must find and bind to a host
cell membrane, inject its virion contents (RNA, reverse
transcriptase, proteins) into the cytosol of the host cell
through membrane fusion or endocytosis, help facilitate
the processing and transport of such contents to the cell
nucleus, and finally integrate its genome into the DNA
of the host cell. After these complex series of events,
the “hijacked” cell is instructed to produce the virion’s
constituent parts that later assemble into new viruses and
escape the host cell [1, 3, 4, 6, 7, 9].
Therapies developed to combat viral infection involve
inhibiting one or several of the above described processes
employed by the virus to infect the target cell [9–11].
For example, in the case of the human immunodeficiency
virus (HIV), enfuvirtide (T-20) inhibits fusion of the viral
membrane with that of the host cell [12] while zidovudine,
didanosine, and zalcitabine inhibit reverse transcription
of RNA into integration-ready DNA [13]. Elvitegravir,
dolutegravir, and raltegravir inhibit DNA integration in
the nucleus, blocking the insertion of the viral genome
∗Electronic address: tomchou@ucla.edu
into the host DNA [14], while darunavir, saquinavir, and
fosamprenavir inhibit HIV-1 protease activity which en-
sures the proper cleavage of viral polypeptide chains [15].
Fusion inhibitors, the latest class of anti-viral drugs to be
developed, are now integrated into overall therapy and
have the advantage of inhibiting the virus at the first step
of the infection process. In principle, the employment of
fusion inhibitors can reduce the need for intracellularly
targeted therapies which often result in additional side-
effects, require higher drug concentrations, and involve
more complicated pharmacokinetics [12].
In order to design and assess the effectiveness of vi-
ral entry inhibitor treatments, a quantitative description
of the viral entry process is necessary [16, 17]. Since a
complete biological picture is still elusive, mathematical
models that include relevant mechanisms such as surface
receptor binding, dissociation, viral degradation, and vi-
ral fusion can allow us to explore several aspects of the
viral entry process, such as the influence of multiplicity of
infection and stoichiometry of receptor/coreceptor bind-
ing. Once appropriate models are derived, a statistical
inference can be performed using data from experimental
measurements of viral entry to validate assumptions and
to obtain constraints on the model rate parameters.
HIV-1 is an enveloped virus that follows a receptor-
coreceptor binding paradigm [1, 3, 7, 18]. It has evolved
to target helper T-cells of the human immune system.
Helper T-cells express the membrane surface receptor
CD4 which normally functions as a coreceptor to the T-
cell receptor (TCR) complex. Both the TCR and CD4
2bind to the MHC class II protein complex of antigen-
presenting cells (APC) prior to the initiation of cytokine
release, activation of cytotoxic T-cells and antibody pro-
ducing B-cells, and other secondary immune response
processes [3].
HIV-1 binds to CD4 with its glycoprotein spike, Env,
upon contact with the cell surface of the helper T-cell
[1, 4, 7, 18]. Env is formed by a trimer of a pair of
glycoprotein subunits: gp120 and gp41. The former sub-
unit contains a CD4 binding domain and five variable
chain regions. The complex gp41 anchors gp120 to the
viral membrane via a non-covalent bond and is central to
the fusion process of infection [19, 20]. After binding to
CD4, gp120 goes through a conformational change that
exposes an occluded binding domain that binds to a cell
surface coreceptor. Though many coreceptors have been
identified and are used differentially depending on the
HIV-1 strain, the two that are by far the most prevalent
are CCR5 and CXCR4 [1, 21]. HIV-1 that bind CCR5
are called R5 strains and are the most common variant
involved in transmission of the virus between individu-
als while the strains that bind CXCR4, R5X4, normally
manifest later in the disease, possibly due to the depletion
of CCR5 expressing T-cells [5]. For the rest of this study
we will focus only on the R5 strain of HIV-1 and consider
CCR5 as the main coreceptor. After the Env complex has
bound to CCR5, it undergoes a further conformational
change that exposes gp41 which extends and penetrates
the host cell membrane [1, 20], bringing the cellular and
viral membranes to close proximity and allowing them
to fuse. After successful viral entry, the capsid coat dis-
solves and HIV-1 RNA is reverse transcribed to DNA,
transported into the nucleus, and finally integrated into
the host DNA. The cell will now produce the constituent
parts needed to assemble more HIV-1 virions.
Since binding of surface receptor CD4 and coreceptor
CCR5 are fundamental steps in viral entry, we expect
the infectivity of most strains of HIV-1 to be particu-
larly responsive to the cell surface density of those recep-
tors. This response has been investigated using the 293-
Affinofile cell line system [22, 23]. Affinofile cells are a
CD4/CCR5 dual-inducible cell line capable of expressing
independent combinations of surface expression of CD4
and CCR5 [22]. CD4 expression is induced with minocy-
cline or doxycycline, protein synthesis inhibitors used in
antibiotics, and CCR5 is induced with ponasterone A,
an ecdysteroid activity inducer. Once induced, Affinofile
cells can be infected with reporter-pseudotyped HIV-1
particles or live virus in a spinoculation protocol where
virions are exposed to a layer of plated cells. Infection
is then quantified through reported expression or intra-
cellular staining for expression of p24, the capsid protein
HIV-1 uses to form a protein coat [22, 24, 25]. By fol-
lowing this protocol, Johnston et al. [22] measured the
infectivity of a number of HIV-1 strains on cells that ex-
pressed a matrix of varying levels of CD4 and CCR5.
Once the levels of p24 are measured, viral infectivity can
be directly related to the associated CD4 and CCR5 con-
centrations used.
In their analysis, Johnston et al. [23] argued that viral
infectivity as functions of CD4 and CCR5 concentrations,
[CD4] and [CCR5] respectively, could be qualitatively fit
to a quadratic polynomial function
Fquad(x, y) = a+ bx+ cy + dx
2 + ey2 + fxy, (1)
representing the amount of viral particle entry measured
through the percentage of cells that are p24+. The inde-
pendent variables x and y are rescaled concentrations of
CD4 and CCR5, respectively, defined as:
x =
log
(
[CD4]
[CD4]min
)
log
(
[CD4]max
[CD4]min
) , y = log
(
[CCR5]
[CCR5]min
)
log
(
[CCR5]max
[CCR5]min
) . (2)
In Eqs. 2, [CD4]min, [CD4]max and [CCR5]min,
[CCR5]max are the minimum and maximum expression
levels of receptor and coreceptor, respectively, used in a
given measurement. The rescaling in Eqs. 2 restricts x
and y to be between 0 and 1 and is used to compare
results obtained from different experiments and/or pro-
tocols that may have yielded different absolute ranges
of [CD4] and [CCR5]. The parameters a,b,c,d,e, and f
are estimated from fitting Fquad to data. Three metrics
were derived from Fquad(x, y): the mean relative infec-
tivity M , and the amplitude ∆ and angle θ of the aver-
age infectivity gradient, ~S =
∫ 1
0
∫ 1
0
~∇Fquad(x, y)dxdy =
Sxxˆ+ Sy yˆ. These were defined as:
M =
∫ 1
0
∫ 1
0
Fquad(x, y)dxdy,
∆ = |~S|,
θ = tan−1
(
Sx
Sy
)
. (3)
M characterizes of the overall relative infectivity of a
strain of HIV-1, while ∆ and θ quantify how respon-
sive a given strain is to receptor and coreceptor con-
centrations. For example, a θ value close to 0◦ implies
Sx ≪ Sy and indicates infectivity that is very respon-
sive to CD4 expression levels, while a value close to 90◦
implies Sx ≫ Sy and indicates a high responsiveness to
CCR5 levels, as shown in Fig. 1. Johnston et al. [23]
observed this latter pattern in several virus strains that
exhibited apparent unresponsiveness to CD4, even at ex-
tremely low CD4 concentrations, leading to the possibil-
ity of an effectively “CD4-independent” pathway for viral
entry. A complete mechanistic picture of the molecular
processes involved however is lacking and the current em-
pirical evidence is insufficient to conclusively argue for a
completely CD4-independent entry pathway. Although
fitting data to Fquad(x, y) provides a functional relation-
ship between receptor and coreceptor concentrations and
3FIG. 1: Quantitative analysis of infectivity measurements over a matrix of CD4 and CCR5 expression levels on Affinofile
cells. The displayed data is a measurement of the infectivity of strain NL43(RT) [22]. (a) Normalized data of relative HIV-
1 infectivity, Fdata, as a function of rescaled concentration of receptor CD4 and coreceptor CCR5. Fdata is measured as a
percentage of cells expressing p24 protein; an indicator of successful HIV-1 infection. (b) Fitted quadratic function, Fquad(x, y),
of percentage of infected cells as a function of rescaled CD4 and CCR5 concentrations. The average infectivity relative to the
maximum observed is M = 52.5. (c) Gradient map of the quadratic fit, Fquad(x, y), displays how responsiveness differs for
different concentrations. The responsivity magnitude here is ∆ = 68.2 and the responsivity angle is θ = 81.7◦.
viral infectivity, and descriptive parameters characteriz-
ing that relationship, the fitted function Fquad(x, y) of-
fers no mechanistic insight into the relevant biochemical
processes or their rates. Essentially, the parameters M ,
∆, and θ are not directly related to mechanistic param-
eters involved in viral entry, especially those that could
be potentially altered by fusion inhibitors or other thera-
peutics. Finally, although in previous work different viral
strains were tentatively clustered as a function of their
receptor and coreceptor usage patterns [22, 23], a mech-
anistic model, where kinetic rates carry a biochemical
significance, allows us to place greater confidence in the
validity of experimentally derived rates, especially if es-
timates from different viral strains cluster in parameter
space.
In this paper, we seek to quantitatively characterize
HIV-1 infectivity as a function of cell surface concentra-
tions of CD4 receptor, CCR5 coreceptor, and the associ-
ated kinetic rates. We propose three alternative models
for receptor/coreceptor engagement and validate them
against experimental data derived from the Affinofile cell
system and derive estimates for kinetic parameters using
maximum likelihood estimation (MLE). Furthermore, we
cluster the parameter estimates from experiments derived
from the same viral strains to demonstrate confidence in
our inference. Lastly, we consider model selection crite-
ria to compare the performance of our proposed models
and assess their utility in modeling HIV-1 infection.
II. THEORY
A. Sequential Model
The simplest model of HIV-1 viral entry is based on
the assumption that binding of the viral Env protein com-
plex to cell surface receptor CD4 is a necessary precur-
sor step for viral entry [1, 4, 18]. This binding causes
Env to undergo a conformational change that allows fur-
ther binding to the CCR5 coreceptor, initiating the fusion
event. We display this “sequential” binding assumption
with rate parameters and pathways in Fig. 2. We de-
note the concentration [V] (number per host cell area)
of membrane-associated HIV-1 virion particles which are
not bound to any receptors by c0(t), the concentration
[V-CD4] of CD4 receptor-bound HIV-1 by c1(t), and the
concentration [V-CD4-CCR5] of HIV-1 bound to both
CD4 and CCR5 by c2(t), at a given time t. In addi-
tion, we include a potential fusion inhibitor and denote
by c∗2(t) the concentration [V-CD4-CCR5*] of HIV-1 that
is bound to CD4 and CCR5 and to an external peptide
that impedes fusion, effectively sequestering the cell from
further progressing towards infection. Although there are
many intermediate steps during membrane fusion and in-
side the cytoplasm that ultimately result in viral DNA
integration, we subsume these processes into a single step
that follows the assembly of the V-CD4-CCR5 complex in
the rate parameter kint. We also assume the adsorption
rate, kon(t), of free virus onto the cellular surface is time
dependent since cell adhesion is high during spinocula-
tion when the HIV-1 viruses are driven close to the cell
membrane [8]. After spinoculation, the culture medium
is replaced to wash away free virus particles. Therefore,
for times t > 0 adsorption of new HIV-1 to the mem-
brane is precluded and we set kon(t > 0) = 0. Finally,
while koff describes the rate of HIV-1 desorption from
the cell membrane, µ1 and µ2 describe the rate of CD4
or CCR5-bound virus elimination via capsid protein coat
degradation, endocytosis, or other abortive events. Us-
ing these assumptions, we can mathematically describe
the sequence of events leading to infection for t > 0 as
4FIG. 2: Sequential kinetic model of viral entry. HIV-1 viruses that are associated with the host membrane, V, are adsorbed
with rate kon and dissociate with rate koff . They can then bind to CD4 receptors to become V-CD4 with rate k+1 from
which they can unbind with rate k−1 or degrade with rate µ1. The V-CD4 complex can bind to coreceptor CCR5 to become
V-CD4-CCR5 with rate k+2, reverse the process with rate k−2, degrade with rate µ2, or carry on to full cell membrane fusion
and integration with rate kint. We include the peptide-bound state V-CD4-CCR5* to factor in fusion inhibition which would
sequester the CD4 and CCR5 bound viruses with rate kp and degrade with rate µp.
follows:
dc0(t)
dt
= −k+1c0 − koffc0 + k−1c1,
dc1(t)
dt
= k+1c0 − k−1c1 − µ1c1 − k+2c1 + k−2c2, (4)
dc2(t)
dt
= k+2c1 − k−2c2 − kpc2 − kintc2 − µ2c2 + k−pc
∗
2,
dc∗2(t)
dt
= kpc2 − k−pc
∗
2 − µpc
∗
2.
The above equations represent the concentration flow in
and out of the four states the virus can inhabit, V, V-
CD4, V-CD4-CCR5, and V-CD4-CCR5*, respectively, as
detailed in Fig. 2. For example, the three terms in the
first equation, from left to right, describe HIV-1 binding
to CD4, HIV-1 desorbing from the cell membrane, and
CD4-bound HIV-1 dissociating from CD4 while main-
taining cell adhesion. We adopt the simplest assumption
that the overall receptor and coreceptor binding rates k+1
and k+2 are increasing functions of the surface expression
of CD4 and CCR5, respectively, and define
k+1 = k
0
+1[CD4]
β1 and k+2 = k
0
+2[CCR5]
β2 , (5)
where k0+1 and k
0
+2 are the intrinsic binding rates be-
tween Env and the respective receptors CD4 and CCR5.
The stoichiometry, β1 and β2, represent, in the infinitely
cooperative binding limit, the number of receptors and
coreceptors that must bind before fusion can be triggered
[26, 27]. For example, Env is known to form a trimer
of gp120/gp41 complexes, with each subunit containing
a CD4 binding domain [1, 18, 28]. If typically two or
more of these binding domains are required to be bound
to CD4 receptors before the appropriate conformational
changes occur, we expect the associated Hill coefficient
β1 > 1.
Within our mathematical model, we represent HIV-1
infectivity by
Q(t) =
∫ t
0
kintc2(τ)dτ, (6)
FIG. 3: (a) Infectivity Q(t) calculated from Eq. 6 using differ-
ent values of β1 and setting all other rates to 1s
−1. Since the
Env trimer has three possible binding domains for CD4, in-
fectivity will increase if the complex exhibits infinite binding
cooperativity across two or three of the subunits. (b) Ef-
fectiveness of fusion inhibitor on total viral infectivity Q∞
defined in Eq. 7 as a function of varying peptide binding
rate kp. We plot the resulting curves for different values of
Kp = µp/k−p while setting all other rate parameters to 1s
−1
and β1 = β2 = 1. Since kp scales with the concentration of
fusion inhibitor peptide, increasing the latter inhibits HIV-
1 infectivity more effectively at lower peptide concentrations
than at higher ones.
the fraction of initially-adsorbed virus particles that that
have undergone fusion by time t. Q(t) represents the cu-
mulative number of successful fusion events from state
V-CD4-CCR5. Once the relevant rates are determined,
given an initial concentration of adsorbed virus, c0(0) ≡
V0, and assuming no other bound complexes so that
c1(0) = c2(0) = c3(0) = 0, we can derive Q(t) from
Eqs. 5 and compare analytical results with the experi-
mental measurements of viral infection on Affinofile cells
[23, 25]. The qualitative behavior of Q(t) for various
β1 is shown in Fig. 3(a) assuming a hypothetical case
where all rates are set to 1s−1. The plot shows an ini-
tial steep increase of viral infectivity immediately after
t = 0 as viruses progress toward receptor and coreceptor
binding and fusion. Eventually the initial concentration
of HIV-1, V0, is depleted, at which point Q(t) flattens
out. We expect larger values of β1 to yield larger values
5of Q(t) since they allow for stronger binding, while the
β1-independent dissociation and degradation rates stay
the same. Since viral infectivity is measured after a suffi-
ciently long exposure time we focus on the long time value
Q∞ ≡ limt→∞Q(t). Upon solving Eqs. 5 and Eq. 6, we
find
Q∞ =
V0(
ω−k
−2
kint
)
+
(
koff (ω−k−2)
k+1kint
)
+
(
ωµ1
k+2kint
)
+
(
ωkoff (k−1+µ1)
k+1k+2kint
) , (7)
where
ω = k−2 + kint +
(
µp
k−p + µp
)
kp + µ2. (8)
The quantity ω can be interpreted as the total flow of
virus out of the state V-CD4-CCR5 as the individual
terms describe, from left to right, the dissociation of
CCR5, viral membrane fusion, fusion inhibiting peptide
binding, and V-CD4-CCR5 complex degradation. Note
that, through the rate parameters k+1 and k+2 (Eqs. 5),
Q∞ is a function of the concentrations [CD4] and [CCR5].
As evident from Eq. 7, the total infectivity depends
on rates of known kinetic processes and initial viral con-
centrations. Measuring the effects of each of these pa-
rameters on Q∞ is particularly useful in the study and
development of drug therapies. For example, if we make
the reasonable assumption that the fusion inhibitor pep-
tide binding rate kp is proportional to the concentration
of the peptide in the extracellular environment, we may
vary kp while keeping all other parameters fixed and ob-
serve how infectivity changes, as depicted by the dose-
response curves in Fig. 3(b). Here, increasing kp leads to
a more pronounced decrease in infectivity Q∞ at low kp,
while for high values of kp, changes in Q∞ are less sig-
nificant. Thus, our analyses of the model can be used to
guide, based on mechanistic principles, the development
and administration of entry inhibitor therapeutics.
III. RESULTS & DISCUSSION
In order to compare experiments from a number of
different HIV-1 strains, cell lines, and laboratory con-
ditions, rescaled expression levels of CD4 and CCR5, x
and y, respectively, are used. Solving Eqs. 2 for [CD4]
and [CCR5], we can express the rates k+1 and k+2 as
functions of x and y. We find k+1 = k
0
+1[CD4]
β1 =
k0+1[CD4]
β1
min
(
[CD4]max
[CD4]min
)β1x
and k+2 = k
0
+2[CCR5]
β2 =
k0+2[CCR5]
β2
min
(
[CCR5]max
[CCR5]min
)β2y
. Furthermore, as V0 in
Eq. 7 has units of concentration, so does Q∞. To nondi-
mensionalize the expression in Eq. 7 and allow for direct
comparisons of results across different experiments, we
can normalize Q∞ by a reference virus concentration.
Experimentalists commonly use the raw infectivity value
corresponding to the highest concentrations of CD4 and
CCR5 as the reference concentration [22, 29]. If we de-
fineQmax as the experimental infectivity at [CD4]max and
[CCR5]max, the normalized infectivity becomes
F∞(x, y|ξ) ≡
Q∞
Qmax
=
D
1 +AXβ1x +BY β2y +ABCXβ1xY β2y
,(9)
where X = [CD4]min[CD4]max and Y =
[CCR5]min
[CCR5]max
are experiment-
dependent constants and ξ ≡ {A,B,C,D, β1, β2} is a
six-dimensional vector of parameters. The dimensionless
combination of parameters A, B, C and D are defined
by
A =
(
1
[CD4]min
)β1 ( koff
k0+1
)
,
B =
(
1
[CCR5]min
)β2 µ1ω
k0+2 (ω − k−2)
, (10)
C =
(
1 +
k−1
µ1
)
,
D =
kintV0
Qmax(ω − k−2)
.
For illustration, in Fig. 4 we plot F∞(x, y|ξ) for three
different sets of ξ. In Fig. 4(a), we assume a small value of
the dimensionless parameter B, while in Fig. 4(b) we as-
sume a small dimensionless parameter A. In Fig. 4(c), we
set A = B but we assume different stoichiometries β1 = 5
and β2 = 1. All values of the chosen parameters ξ are pre-
sented in the figure caption. The different sets of param-
eters yield model infectivity functions F∞(x, y|ξ) with
gradients along various directions in the (x, y) plane, in-
dicating greater sensitivity to [CD4] or [CCR5]. Further-
more, higher values of stoichiometry β1, β2 amplify the
sensitivity over a range of concentration values. There-
fore, F∞(x, y|ξ) may effectively represent different viral
strains with different CD4/CCR5 usage patterns distin-
guished by values of ξ.
Before fitting to data to find the MLE of ξ, we note
that even though Qmax is a known constant from the raw
infectivity data, some previous data sets do not report its
6FIG. 4: F∞(x, y|ξ) for different sets of ξ. (a) For (A,B,C,D, β1, β2) = (20, 2, 1, 1, 2, 2), the infectivity is most sensitive to x, or
[CD4]. (b) For (A,B,C,D, β1, β2) = (2, 20, 1, 1, 2, 2), the function F∞ varies more along the y direction and infectivity is more
sensitive to [CCR5]. (c) (A,B,C,D, β1, β2) = (20, 20, 1, 1, 10, 2). Note that A and B predominately control the direction (CD4
or CCR5) of sensitivity, and β1, β2 control the steepness of the infectivity surface.
value [22, 29]. Therefore this normalization factor is sub-
sumed into the inference of D but still can be inferred
provided the other parameters forming D can be inde-
pendently determined.
If we wish to fit raw unnormalized infectivities, we can
also use the form for F∞(x, y|ξ) directly, but redefine
the prefactor D = kintV0(ω−k
−2)
as having the same units as
the experimental output (such as number of cells, fluo-
rescence, etc.). In this case, the parameter D must be
rescaled by an experimental factor with units of the ex-
perimental output multipled by an area. In either case,
we consider the amplitude D as a free parameter to be
inferred from data fitting. This parameter incorporates,
and is confounded by, the initial intensity of exposure,
as well as many of the sample-to-sample experimental
variability arising from instrument error, host cell num-
ber, and area within each sample well. Therefore, we
do not expect the effective values of D to systematically
represent intrinsic kinetic rates. However, we do expect
the remaining parameters A,B,C, β1, and β2 to influ-
ence the shape of F∞(x, y|ξ) and the receptor/coreceptor
usage patterns. Note that in addition to the intrinsic
rate parameters, A and B also depend on [CD4]min and
[CCR5]min which can vary from from one measurement
to the next. Therefore, direct comparisons of A and B
can be made only across measurements that use the same
[CD4]min and [CCR5]min.
We now fit F∞(x, y|ξ) to previously-obtained normal-
ized infectivity by finding the maximum likelihood val-
ues for ξˆ = (Aˆ, Bˆ, Cˆ, Dˆ, βˆ1, βˆ2). The appropriate likeli-
hood function is based on the assumption that chemical
kinetic rates are typically products of positive random
variables representing chemical concentrations and other
rates. This, and the need to restrict the infectivity signal
to strictly positive values implies that a log-normal dis-
tribution for values of F∞ is reasonable. The maximum
likelihood estimation for ξ then equivalent to minimizing
the objective function
Φ(ξ) =
∑
i,j
(logF∞(xi, yj |ξ)− logFdata(xi, yj))
2
, (11)
where Fdata(xi, yj) are measured values of normalized in-
fectivity at rescaled concentrations xi and yj of CD4 and
CCR5 used in the experiments. As a first approximation,
we assume β1 = β2 = 1 and C ≈ 1. This last approx-
imation is valid when the CD4 dissociation rate k−1 is
much smaller than the CD4-bound degradation rate µ1,
a chemically reasonable assumption. In our subsequent
fits using all parameters (Aˆ, Bˆ, Cˆ, Dˆ, βˆ1, βˆ2), the best-fit
value of Cˆ is indeed near one. Therefore by henceforth
setting β1 = β2 = 1 and C = 1, we reduce the number
of parameters to be estimated from six to three. The
results obtained by fitting the data from several exper-
imental measurements of HIV-1 strains can be found in
Table 1.
In Fig. 5 we plot the fitted curve of F∞(x, y|ξˆ) us-
ing the estimated parameters from viral strain B5(YA)
shown in the fourth line of Table 1, which qualitatively
shows good agreement with the corresponding experi-
mental data. Upon repeating the same analysis on 32
experimental data sets selected from previous publica-
tions [22, 23], we can associate each set of infectivities
with fitted Aˆ-Bˆ-Dˆ values. As expected, infectivities of
the same strain of HIV-1 cluster together in A-B param-
eter space as shown in Fig. 6. To indicate the goodness
of fit to our model, we also calculate and display in Table
1 the coefficient of determination
R2 ≡ 1−
∑
i,j
(
logF∞(xi, yj |ξˆ)− logFdata(xi, yj)
)2
∑
i,j
(
log F¯data − logFdata(xi, yj)
)2 ,
(12)
where F¯data is the measured normalized infectivity aver-
aged over all [CD4] and [CCR5] concentration combina-
tions. The low R2 values suggest that our initial assump-
tion of β1 = β2 = 1 should be relaxed to obtain better
fits.
7FIG. 5: HIV-1 infectivity as a function of CD4 and CCR5 concentrations. The data displayed is from strain B5(YA) [22]. (a)
Normalized unscaled infectivity data measured after a sufficiently long exposure time. (b) Normalized and rescaled infectivity
data in terms of (x, y). (c) Fitted plot of scaled normalized infectivity F∞(x, y|ξˆ) from Eq. 7 assuming C = 1 and β1 = β2 = 1.
The MLE of the remaining parameters are Aˆ = 6.39, Bˆ = 1.56, and Dˆ = 1.09.
FIG. 6: MLE points in A − B − D parameter space in the
context of the sequential kinetic model assuming C = 1. (a)
Fixed β1 = β2 = 1. Each point represents an experiment
for which parameters were estimated. Measurements were
derived from published data [22, 29, 30] and points corre-
sponding to replicate measurements on the same viral strain
are shown in the same color. There is large variation in the
inferred parameters between viral strains, but parameters in-
ferred from replicate measurements on the same strain clus-
ter relatively closely in (A,B) parameter space. As expected,
there is high measurement variability in D. (b) Allowing β1
and β2 to be free parameters to be estimated from fitting.
Here variability in the A, B, and D parameters increase as
they become less sensitive to the functional form presented
in Eq. 9 to compensate for the high sensitivity of the stoi-
chiometric parameters β1 and β2. Here, we include only rep-
resentative data points that clustered, confirming the large
variability in parameter estimates.
We thus consider the role of stoichiometry of receptor
and coreceptor binding by reintroducing β1 and β2 as
free parameters and perform maximum likelihood fitting
using five parameters ξ = (A,B,D, β1, β2), again using
the approximation C = 1. The fitted function is shown
in Fig. 7 which is qualitatively different from Fig. 5.
The new estimated parameters using the same data as
before are displayed in Table 2. Here, the residual values
R2 are higher, indicating a much better fit of the data
when β1, β2 are adjustable. The kinetic model F∞(x, y|ξ)
in Eq. 7 consistently outperforms the quadratic model
Fquad(x, y) introduced earlier.
The value of βˆ2 is consistently close to 1 which indi-
TABLE I: Fitted parameters of sequential kinetic model as-
suming C = 1 and β1 = β2 = 1 for six different exper-
iments representing triplicate measurements of two HIV-1
strains. The parameters are in close agreement within each
viral strain. R2 values are shown with low values implying
the β1 = β2 = 1 assumption is overly constraining.
Strain-Experiment Aˆ Bˆ Dˆ R2
B5 (YA)-Rep1 6.39 1.56 1.09 0.64
B5 (YA)-Rep2 6.03 1.53 1.27 0.64
B5 (YA)-Rep3 5.91 1.34 1.49 0.66
B5 (RT)-Rep1 3.77 3.80 1.1 0.60
B5 (RT)-Rep2 4.18 4.25 1.17 0.68
B5 (RT)-Rep3 4.58 3.87 1.13 0.64
cates that coreceptor binding only involves a single CCR5
for fusion to be initiated. The value of βˆ1, on the other
hand, is much larger. If interpreted as a binding stoi-
chiometry, this would indicate that multiple gp120/gp41
complexes of the Env trimer must bind to separate CD4
receptors before conformational changes can take place.
Our results, however, show β1 > 3, which indicates that
each individual gp120/gp41 complex binds to multiple
CD4 receptors. Alternatively, the large exponent β1 can
describe high allosteric cooperativity of Env or the dy-
namics of multiple Env each binding to CD4, increasing
the effective rate of CCR5 binding. To quantify our confi-
dence in this result, we take a closer look at the objective
function Φ(ξ) in Eq. 11 and evaluate it for ξ values close
to ξˆ, the optimal value of ξ that minimizes Φ(ξ) con-
strained by the data. By varying one of the parameters
at this minimum while keeping all others fixed, we can
measure the rate of change in Φ(ξ) with respect to that
parameter. In particular, we can determine the sensitiv-
ity of the model with respect to a given parameter by
evaluating the curvature of Φ(ξ), a measure of fit error,
along the direction in which that parameter changes, as
shown in Fig. 8.
To compare the performance of the quadratic model
described by Fquad(x, y) with that of our kinetic model
8FIG. 7: Normalized HIV-1 infectivity as a function of CD4 and CCR5 levels. The data displayed is from strain B5(YA) [22].
(a) and (b) are identical to the first two panels in Fig. 5. (c) Fitted plot of scaled normalized infectivity F∞(x, y|ξˆ) with C = 1
but free β1, β2. The MLE of the parameters are Aˆ = 17, Bˆ = 1.84, Dˆ = 0.96, βˆ1 = 11.7, and βˆ2 = 0.8.
TABLE II: Fitted parameters of the sequential kinetic model assuming C = 1 for six sets of measurements, three replicates
of each of two different strains of HIV-1. The MLE parameter values are in close agreement within each viral strain. R2
values are calculated for both the arbitrary quadratic model introduced earlier and the sequential kinetic model (Fig. 2). The
mechanism-based kinetic model consistently outperforms the quadratic model.
Strain-Experiment Aˆ Bˆ Dˆ βˆ1 βˆ2 R
2: Fquad R
2:F∞
B5 (YA)-Rep1 17.04 1.84 0.96 11.7 0.79 0.95 0.96
B5 (YA)-Rep2 16.40 2.62 1.49 11.6 0.57 0.94 0.98
B5 (YA)-Rep3 14.85 2.30 1.73 10.8 0.55 0.80 0.97
B5 (RT)-Rep1 10.67 3.15 0.79 13.9 1.29 0.79 0.90
B5 (RT)-Rep2 9.90 9.42 2.01 10.7 0.68 0.77 0.92
B5 (RT)-Rep3 12.32 3.30 0.81 12.1 1.23 0.81 0.92
FIG. 8: Projections of Φ(ξ) about the minimum at
(Aˆ, Bˆ, Cˆ, Dˆ, βˆ1, βˆ2) = (17, 1.84, 1, 0.96, 11.7, 0.8). (a) Projec-
tion on (A,β1) space. (b) Projection on (B, β2) space.
described by F∞(x, y|ξˆ) both with β1 = β2 = 1 and
as free parameters, we calculate the Akaike Information
Criterion (AIC) score
AIC = 2n+
∑
i,j
log
(
2πF 2data(xi, yj)
)
(13)
+
∑
i,j
(
logF∞(xi, yj|ξˆ)− logFdata(xi, yj)
)2
,(14)
a standard statistical measure for model comparison and
selection. In Eq. 14, n is the number of inferred parame-
ters in the model and the last two terms are derived from
the log-likelihood function of the infectivity distribution.
The AIC score penalizes models with large errors in the
TABLE III: AIC scores, defined in Eq. 14, for the arbitrary
quadratic model, our sequential kinetic model assuming C =
1 and β1 = β2 = 1, and the same model with now β1, and
β2 as free parameters to be estimated. The latter model has
shown to consistently outperforms both the fixed β1, β2 model
and the quadratic model introduced earlier.
Strain- AIC:Fquad AIC:F∞ AIC:F∞
Experiment (β1 = β2 = 1) (free β1,β2)
B5 (YA)-Rep1 -19.9 -7.30 -22.4
B5 (YA)-Rep2 -1.80 9.20 -6.0
B5 (YA)-Rep3 26.0 28.2 15.6
B5 (RT)-Rep1 -31.4 -25.7 -39.4
B5 (RT)-Rep2 -35.5 -36.0 -45.2
B5 (RT)-Rep3 -38.0 -32.9 -46.1
prediction of each data point and with too many fitted
parameters, so a low AIC score is ideal. We observe
that the kinetic model with β1 and β2 as free parame-
ters once again outperforms both the models with fixed
β1 = β2 = 1 and the quadratic model, further validating
our mechanistically derived model. This implies that the
data provides some confidence in a higher stoichiometry
β1 > 1.
Once accurate estimates of the model parameters A,
B, D, β1, and β2 are obtained from minimizing Φ(x, y|ξ),
we can derive constraints on the physical rate parameters
through Eqs. 10. Although there are more kinetic param-
eters to solve for than available estimates, we can use
known rate values obtained from past ligand binding as-
9says [31, 32]. For example, Chang et al. [33] set the Env-
CD4-CCR5 dissociation rate at k−2 ≈ 1.7s
−1. Further-
more, if we assume all degradation rates are equal, we can
follow Seisenburger et al. [32] and use µ1 = µ2 ≈ 15s
−1
as general viral degradation rates. Furthermore, through
GFP genetic marking and flow cytometry, assays can be
designed to potentially measure the nonspecifically ab-
sorbed virus dissociation rate koff [34].
The data shown in Fig. 1 reveals that the entry of the
associated viral strain is very insensitive to CD4 levels for
the values explored. Using the previous metrics defined
in Eqs. 3, the sensitivity vector ~S points almost entirely
in the y (CCR5) direction. Previous work has also sug-
gested the existence of “CD4-independent” strains that
infect at extremely low levels of CD4 [35, 36]. However,
our sequential model requires binding of CD4 before fu-
sion can occur. In the next section, we explore an alter-
native and more general “parallel” pathway model that
may better fit observed data such as that illustrated in
Fig. 1.
A. Parallel Model
The quantitative analysis done by Johnston et al.
[22, 23] showed that HIV-1 infectivity of some viral
strains had remarkably low responsiveness to the induced
surface concentrations of CD4 while still having a rela-
tively monotonic dependence on CCR5 concentrations, as
previously shown in Fig. 1. Furthermore, some strains of
simian immunodeficiency virus (SIV) are known to infect
via “CD4-independent” pathways, requiring only CCR5
coreceptor for viral entry [37]. Motivated by these obser-
vations, we propose a “parallel” pathway model wherein
HIV-1 can either enter through the standard pathway
described in the sequential model presented in the last
section, or can either completely bypass CD4 binding.
Within this “parallel” model we propose that HIV-1 can
interact with CCR5 directly with rate p+1 and form the
complex V-CCR5 whose concentration, [V-CCR5], we
denote as c2(t). As shown in Fig. 9, this state can then di-
rectly enter the cell through fusion or endocytosis leading
to infection with rate pint [38]. For mathematical simplic-
ity, we describe the standard sequential model discussed
in the previous subsection via a “lumped” model where
the sequential binding of CD4 and CCR5 is described by
one effective rate.
The corresponding rate equations are:
dc0(t)
dt
= kon(t)− k+1c0 − p+1c0 − koffc0 + k−1c1 + p−1c2,
dc1(t)
dt
= k+1c0 − k−1c1 − µ1c1 − kintc1, (15)
dc2(t)
dt
= p+1c0 − p−1c2 − µ2c2 − pintc2.
Similar to the sequential model, we expect the bind-
ing rates to be functions of the concentrations of
FIG. 9: Parallel kinetic model of viral entry. In this coarse-
grained model, V-CD4-CCR5 effectively represents a virus
that binds to CD4 first and is then bound to CCR5. The top
pathway effectively subsumes the standard sequential entry
pathway into a single step. Alternatively, we suppose that
the virus can interact with CCR5 directly and also infect the
cell with rate pint. This is the simplest model that provides a
“CD4-independent” entry pathway.
CD4 and CCR5: k+1 = k
0
+1[CD4]
β1 [CCR5]β2 , p+1 =
p0+1[CCR5]
γ1 , where k0+1 and p
0
+1 are the intrinsic bind-
ing rates between the virus and the respective receptors
and β1, β2, and γ1 are effective stoichiometries. The total
infectivity is now given by
Q(t) =
∫ t
0
[kintc1(τ) + pintc2(τ)] dτ. (16)
To further simplify matters, we set all degradation rates
equal so that µ1 ≈ µ2 = µ. Upon solving Eqs. 15 and
16, and normalizing by the reference concentration Qmax
from the infectivity data associated with [CD4]max and
[CCR5]max, we find the normalized infectivity to be
F∞ ≡
Q∞
Qmax
=
A1Y
γ1y +A2X
β1xY β2y
Xβ1xY β2yY γ1y +B1Y γ1y +B2Xβ1xY β2y
,(17)
where
A1 =
kintV0
Qmaxkoff
k0+1 [CD4]
β1
min [CCR5]
β2
min
µ+ kint + k−1
,
A2 =
pintV0
Qmaxkoff
p0+1[CCR5]
γ1
min
µ+ pint + p−1
, (18)
and
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B1 =
(µ+ kint)k
0
+1[CD4]
β1
min[CCR5]
β2
min
koff(µ+ kint + k−1)
,
B2 =
(µ+ pint)p
0
+1[CCR5]
γ1
min
koff(µ+ pint + p−1)
. (19)
Note that our simplified parallel model has an additional
parameter compared to that of the sequential model. We
can now perform maximum likelihood statistical analysis
using our parallel pathway model. In Fig. 10 we show the
data of the NL43(RT) strain from Johnston et al. [22].
The fitted surface F∞(x, y|ξˆ) shows a qualitatively good
fit to the data. Not surprisingly, βˆ1 ≈ 0, indicating the
independence of CD4 attachment on [CD4].
In this case, the AIC score yields AIC(parallel) = 3.62
and AIC(sequential) = -1.3, suggesting that the parallel
pathway model is not statistically warranted even for a
highly “CD4-independent” strain. Although there are
only seven parallel pathway parameters versus six for
the sequential model, the parallel model lumps CD4 and
CCR5 binding into a single process which may be too
coarse a description. We test this possibility by exploring
this lumped version of the sequential model.
B. Lumped Model
The sequential model explored above assumes that
gp120 binding of CCR5 is contingent on first binding
to the CD4 receptor. Separating the two viral states
V-CD4 and V-CD4-CCR5, which correspond to virus
bound to CD4 and virus bound to both CD4 and CCR5,
factors in the binding and dissociation dynamics between
these states into the expression for infectivity F∞ derived
above. If the rate of transitioning between these two
states is sufficiently fast, it is possible to further simplify
the model by eliminating the intermediate state V-CD4
by assuming that CD4 and CCR5 binding occur simul-
taneously, as shown in Fig. 11. Upon simplifying the
model in this manner, we reduce the parameter space for
which we perform statistical inference. In order to ex-
plore whether this simplification leads to a better model
fit and estimation of physical rate parameters, we start
with the rate equations:
dc0(t)
dt
= −k+1c0 − koffc0 + k−1c1,
dc1(t)
dt
= k+1c0 − k−1c1 − µ1c1 − kpc1 − kintc1 + k−pc
∗
1,
dc∗1(t)
dt
= kpc1 − k−pc
∗
1 − µpc
∗
1. (20)
Within the the lumped model, we expect the rate of
simultaneous CD4 and CCR5 binding to be a function
of both the concentrations of CD4 and CCR5: k+1 =
k0+1[CD4]
β1 [CCR5]β2 , where β1 and β2 are the appropri-
ate stoichiometry parameters, similar to those defined
in the sequential model. Here, the raw infectivity is
Q(t) = kint
∫ t
0 c1(τ)dτ while the normalized rescaled in-
fectivity takes the form
F∞ ≡
Q∞
Qmax
=
C2
1 + C1Xβ1xY β2y
, (21)
where
C1 =
(
1
[CD4]min
)β1 ( 1
[CCR5]min
)β2 ( koffω
k0+1 (ω − k−1)
)
,
C2 =
kintV0
Qmax (ω − k−1)
. (22)
As in the sequential model, the quantity
ω = k−1 + kint +
(
µp
k−p + µp
)
kp + µ1 (23)
can be considered the bulk flow of virus out of the V-
CD4-CCR5 viral state.
Upon comparing AIC scores of AIC(sequential) = 15.6
and AIC(lumped) = 17.6 from the viral strain B5 (YA)
data presented in Johnston et al. [22], we find the se-
quential model yields a better fit to the data, despite the
reduction of the number of parameters in the lumped
model. Fits are shown in Fig. 12. As in the sequential
model, β1 dictates the sharpness of the descent of F∞ for
very low values of [CD4], but the terms that define the
tilt of the broader region of the function are lost in the
lumped model, preventing an adequate fit of the average
slope of the data. This signifies that the intermediate
process of CD4 binding prior to CCR5 binding is a nec-
essary inclusion into the model.
IV. CONCLUSIONS
In order to distinguish different strains of HIV-1 via
their entry kinetics, heuristic metrics have been derived
to classify different sensitivities of infection to CD4 and
CCR5 expression in the host cell [22]. The metrics M ,
∆, and θ in Eqs. 3 are good discriminators and clus-
ter experimental replicates of identical strains of HIV-1
sufficiently due to the fact that they are purely based
on the shape of the data, but not on any mechanistic
processes involved in viral entry. Here, we analyzed a se-
quential kinetic binding model of HIV-1 viral entry that
yields a functional relationship between the infectivity of
a strain of virus and the levels of CD4 and CCR5 based on
known chemical processes. Our model provides a frame-
work in which to analyze different strains of HIV-1 based
on combinations of parameters in the kinetic model and
physical insight into how these parameters facilitate or
inhibit HIV-1 viral entry. One can now distinguish dif-
ferent strains of HIV-1 according to the inferred values
of kinetic parameters and display the infectivity of each
strain as points in parameter space with physical mean-
ing.
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FIG. 10: Fitting of the parallel model to the data presented in Fig. 1, which appears “CD4-independent.” (a) Raw normalized
infectivity data Fdata as in Fig. 1(a). (b) Scaled normalized data. (c) Best-fit plot using maximum likelihood on the parallel
model. The maximum likelihood parameters are (Aˆ1, Aˆ2, Bˆ1, Bˆ2, βˆ1, βˆ2, γˆ1) = (0.23, 0.26, 1.5, 0, 0, 1.5, 2) and captures the
insensitivity to x ([CD4]).
FIG. 11: Lumped kinetic model of viral entry. The model
simplifies the sequential model in Fig. 2 by subsuming the
intermediate step of HIV-1 binding to CD4 into rate k+1 so
that the virus binds to both CD4 and CCR5 simultaneously.
In addition to kinetic rates, stoichiometries of CD4 and
CCR5 are incorporated in our model. In fact, the depen-
dencies of the infectivity to CD4 and CCR5 levels are
most sensitive to their respective stoichiometries at the
expense of the sensitivity of the other estimated parame-
ters. We show that overall infectivity data is sufficient to
provide some confidence in assigning nonunit stoichiome-
tries, suggesting that on average either multiple CD4s
bind to a gp spike, or multiple gp spikes are engaged in
a typical entry event. In fact, due to the high sensitivity
of the characteristic shape of the infectivity function to
stoichiometry, we suggest that experiments be designed
to increase the number of data points in regions of high
gradients of Fdata(x, y), where the stoichiometric param-
eters β1,2 exhibit the most influence. In this same re-
gard, choosing the minimum and maximum values for
the CD4 and CCR5 experimental inputs dictates the rel-
ative sizes of the constants X and Y , thus altering the
relative sensitivity between the two stoichiometric pa-
rameters. These properties of F∞(x, y) provide guidance
to the experimentalist in designing the most informative
measurements.
Finally, in order to address the existence of strains that
are highly insensitive to CD4 expression, and that in-
fect cells with extremely low levels of CD4, we proposed
a parallel pathway model that allows slow entry, even
in the absence of CD4, through, perhaps, an endocy-
totic mechanism [38]. Here, binding to CCR5 is suffi-
cient to allow for viral entry through an alternate path-
way. We performed parameter inference on this parallel
model and compared our results with those from the orig-
inal sequential model. We also explored a simplification
of the sequential model by subsuming the intermediate
CD4 binding process into one combined process of si-
multaneous CD4 and CCR5 binding. We compared the
performance of this last lumped model with the sequen-
tial model to determine what effects such simplifying as-
sumptions might have on the inference capabilities of our
models.
The modeling and data analysis framework we devel-
oped in this work may also be used to quantify the effec-
tiveness of fusion inhibitors. For example, though fusion
inhibitors can arrest the fusion process at an intermedi-
ate step [39], the bond between gp120 and gp41 is non-
covalent and weak enough so there is a high probability
of this bond breaking, resulting in the virus dissociating
from the cell [19]. Though the Env spike used in that
failed infection attempt is now non-functional, the virus
can theoretically return to the cell and make another at-
tempt with a different Env on its membrane. But unlike
simian immunodeficiency virus (SIV) that is covered in
large amounts of spikes [40], HIV-1 has relatively small
numbers of Env on its surface; often on the order of five
spikes per virus [41]. Thus fusion inhibition becomes a
process of repeated failed attempts at infection of a virus
until the Env spikes are depleted. In this context, two
time scales would be established between the rate of fu-
sion without inhibitor and the rate of depletion of gly-
coprotein spikes. Modeling this aspect of the infectivity
process in the presence of fusion inhibitors can give better
insight into the effectiveness of inhibitor treatment and
recommendations on the duration of possible treatment
protocols. As shown in Fig. 3(b), a model of infectivity
can be used to predict a reduction in viral infection as a
function of fusion inhibitor dosage. Instead of performing
infectivity measurements for varying [CD4] and [CCR5],
we can also change fusion inhibitor levels and study the
12
FIG. 12: A comparison between the lumped model and the sequential model. (a) Scaled normalized data Fdata. (b) Best fitted
plot using maximum likelihood of the sequential model from Fig. 2. (c) Best fitted plot using maximum likelihood of the lumped
model with estimated parameters (Cˆ1, Cˆ2, βˆ1, βˆ2) = (22.0, 0.73, 10.6, 0.37). The lumped model’s functional form, compared to
that of the sequential model, prevents a qualitatively accurate representation of the data, especially in the y-dependence of
Fdata.
corresponding infectivity patterns using the same mod-
els presented in this work. Similar analyses can also be
performed to study the efficacy of broadly neutralizing
antibodies in suppressing viral entry. These and other
physical chemical considerations will be pursued in fu-
ture work involving model analysis and inference from
forthcoming data.
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